NEW YORK – Merck and Moderna announced Wednesday that a Phase III melanoma trial of Keytruda (pembrolizumab) and the personalized cancer vaccine intismeran autogene has met two key endpoints.
The firms will evaluate Ideaya's IDE892 with Genetech's GDC-7035 in MTAP-deleted, KRAS G12D-mutant pancreatic cancer.
The CAR T-cell therapy is the world's first approved for solid tumors and is being tested in a US-based trial.
The firm will use the proceeds to advance neuro-metabolic therapies, including a Phase I/II trial of an antisense oligonucleotide for ALS.
NEW YORK – Eli Lilly has acquired global rights to AlzeCure Pharma's preclinical Alzheimer's disease drug candidate ACD680 after paying the company $10 million upfront, the companies said Tuesday.
The firm reported $11.4 million in net revenue from Zevaskyn for the three months ended June 30, missing analysts' expectations of roughly $12.3 million.
The Chinese biotech said US regulators have cleared it to start trials of the therapy for patients with B-cell lymphoma.
NEW YORK – AstraZeneca on Monday indicated it would seek to expand Enhertu (trastuzumab deruxtecan) and a Tagrisso (osimertinib) combination into new biomarker-defined lung cancer indications based on ...
NEW YORK – Akeso Bio has launched a Phase II study of a bispecific antibody-drug conjugate in combination with its bispecific antibody ivonescimab for advanced breast cancer. The Zhongshan, ...
US regulators are already reviewing data from a later-line trial, but Taiho now says it could seek a first-line indication for the EGFR inhibitor.
The biotech will use the funds to advance its pipeline of epigenetic medicines, starting with its candidate EPI-321 for a type of muscular dystrophy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results